848 related articles for article (PubMed ID: 8810912)
21. Characterization of the zinc finger protein encoded by the WT1 Wilms' tumor locus.
Morris JF; Madden SL; Tournay OE; Cook DM; Sukhatme VP; Rauscher FJ
Oncogene; 1991 Dec; 6(12):2339-48. PubMed ID: 1662794
[TBL] [Abstract][Full Text] [Related]
22. Diaphragmatic hernia in Denys-Drash syndrome.
Devriendt K; Deloof E; Moerman P; Legius E; Vanhole C; de Zegher F; Proesmans W; Devlieger H
Am J Med Genet; 1995 May; 57(1):97-101. PubMed ID: 7645607
[TBL] [Abstract][Full Text] [Related]
23. The WT1 Wilms tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor.
Rauscher FJ
FASEB J; 1993 Jul; 7(10):896-903. PubMed ID: 8393820
[TBL] [Abstract][Full Text] [Related]
24. Altered trans-activational properties of a mutated WT1 gene product in a WAGR-associated Wilms' tumor.
Park S; Tomlinson G; Nisen P; Haber DA
Cancer Res; 1993 Oct; 53(20):4757-60. PubMed ID: 8402654
[TBL] [Abstract][Full Text] [Related]
25. The Wilms' tumor suppressor, WT1, inhibits 12-O-tetradecanoylphorbol-13-acetate activation of the multidrug resistance-1 promoter.
McCoy C; McGee SB; Cornwell MM
Cell Growth Differ; 1999 Jun; 10(6):377-86. PubMed ID: 10392899
[TBL] [Abstract][Full Text] [Related]
26. Wilms' tumor suppressor gene WT1: from structure to renal pathophysiologic features.
Mrowka C; Schedl A
J Am Soc Nephrol; 2000 Nov; 11 Suppl 16():S106-15. PubMed ID: 11065340
[TBL] [Abstract][Full Text] [Related]
27. The novel WT1 gene mutation p.H377N associated to Denys-Drash syndrome.
Guaragna MS; Soardi FC; Assumpção JG; Zambaldi Lde J; Cardinalli IA; Yunes JA; de Mello MP; Brandalise SR; Aguiar Sdos S
J Pediatr Hematol Oncol; 2010 Aug; 32(6):486-8. PubMed ID: 20562648
[TBL] [Abstract][Full Text] [Related]
28. Products of alternatively spliced transcripts of the Wilms' tumor suppressor gene, wt1, have altered DNA binding specificity and regulate transcription in different ways.
Wang ZY; Qiu QQ; Huang J; Gurrieri M; Deuel TF
Oncogene; 1995 Feb; 10(3):415-22. PubMed ID: 7845666
[TBL] [Abstract][Full Text] [Related]
29. A point mutation within exon 5 of the WT1 gene of a sporadic unilateral Wilms' tumor alters gene function.
Guan LS; Liu JJ; Xu YH; Wang ZY
Cancer Res; 1998 Sep; 58(18):4180-4. PubMed ID: 9751632
[TBL] [Abstract][Full Text] [Related]
30. Germline WT1 mutations in Wilms' tumor patients: preliminary results.
Li FP; Breslow NE; Morgan JM; Ghahremani M; Miller GA; Grundy PE; Green DM; Diller LR; Pelletier J
Med Pediatr Oncol; 1996 Nov; 27(5):404-7. PubMed ID: 8827066
[TBL] [Abstract][Full Text] [Related]
31. DNA binding capacity of the WT1 protein is abolished by Denys-Drash syndrome WT1 point mutations.
Little M; Holmes G; Bickmore W; van Heyningen V; Hastie N; Wainwright B
Hum Mol Genet; 1995 Mar; 4(3):351-8. PubMed ID: 7795587
[TBL] [Abstract][Full Text] [Related]
32. The same mutation affecting the splicing of WT1 gene is present on Frasier syndrome patients with or without Wilms' tumor.
Barbosa AS; Hadjiathanasiou CG; Theodoridis C; Papathanasiou A; Tar A; Merksz M; Györvári B; Sultan C; Dumas R; Jaubert F; Niaudet P; Moreira-Filho CA; Cotinot C; Fellous M
Hum Mutat; 1999; 13(2):146-53. PubMed ID: 10094551
[TBL] [Abstract][Full Text] [Related]
33. A novel target for the Wilms' tumour suppressor protein (WT1) is bound by a unique combination of zinc fingers.
Little MH; Holmes G; Pell L; Caricasole A; Duarte A; Law M; Ward A; Wainwright B
Oncogene; 1996 Oct; 13(7):1461-9. PubMed ID: 8875984
[TBL] [Abstract][Full Text] [Related]
34. A point mutation found in the WT1 gene in a sporadic Wilms' tumor without genitourinary abnormalities is identical with the most frequent point mutation in Denys-Drash syndrome.
Akasaka Y; Kikuchi H; Nagai T; Hiraoka N; Kato S; Hata J
FEBS Lett; 1993 Feb; 317(1-2):39-43. PubMed ID: 8381368
[TBL] [Abstract][Full Text] [Related]
35. Homozygous intragenic deletion in the WT1 gene in a sporadic Wilms' tumour associated with high levels of expression of a truncated transcript.
Algar EM; Kenney MT; Simms LA; Smith SI; Kida Y; Smith PJ
Hum Mutat; 1995; 5(3):221-7. PubMed ID: 7599632
[TBL] [Abstract][Full Text] [Related]
36. RNA binding by the Wilms tumor suppressor zinc finger proteins.
Caricasole A; Duarte A; Larsson SH; Hastie ND; Little M; Holmes G; Todorov I; Ward A
Proc Natl Acad Sci U S A; 1996 Jul; 93(15):7562-6. PubMed ID: 8755514
[TBL] [Abstract][Full Text] [Related]
37. Evidence that WT1 mutations in Denys-Drash syndrome patients may act in a dominant-negative fashion.
Little MH; Williamson KA; Mannens M; Kelsey A; Gosden C; Hastie ND; van Heyningen V
Hum Mol Genet; 1993 Mar; 2(3):259-64. PubMed ID: 8388765
[TBL] [Abstract][Full Text] [Related]
38. Contribution of individual amino acids to the RNA binding activity of the Wilms' tumor suppressor protein WT1.
Weiss TC; Romaniuk PJ
Biochemistry; 2009 Jan; 48(1):148-55. PubMed ID: 19123921
[TBL] [Abstract][Full Text] [Related]
39. Proto-oncogene N-myc promoter is down regulated by the Wilms' tumor suppressor gene WT1.
Zhang X; Xing G; Saunders GF
Anticancer Res; 1999; 19(3A):1641-8. PubMed ID: 10470095
[TBL] [Abstract][Full Text] [Related]
40. Denys-Drash syndrome with neonatal renal failure in monozygotic twins due to c.1097G>A mutation in the WT1 gene.
Furtado LV; Pysher T; Opitz J; Lamb R; Comstock J; Batish S; Mauch T; Nelson R; Zhou H
Fetal Pediatr Pathol; 2011; 30(4):266-72. PubMed ID: 21434831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
